NCT01289847 - A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Primary Immune Deficiency DisordersCommon Variable ImmunodeficiencyX-linked AgammaglobulinemiaHyper-IgM SyndromeWiskott-Aldrich Syndrome

Interventions

BIOLOGICAL

Gammaplex

GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.

Trial Locations (10)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

23219

Children's Hospital of Richmond, VA, Richmond

30342

Family Allergy & Asthma Center, PC, Atlanta

52621

Safra Children's Hospital, Sheba Medical Center, Tel Litwinsky

60612

Rush University Medical Center, Chicago

75063

Allergy, Asthma & Immunology Clinic, P.A, Irving

80112

IMMUNOe International Reseach Centers, Centennial

90027

Children's Hospital Los Angeles, Los Angeles

8380418

Hospital de Niňos Roberto del Río, Santiago

92697.

Department of Medicine, University of California, Irvine